Log in

Relevant bibliographies by topics / Prophylaxis Response / Journal articles

To see the other types of publications on this topic, follow the link: Prophylaxis Response.

Journal articles on the topic 'Prophylaxis Response'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Prophylaxis Response.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Starr, Michael B., Gholam A. Peyman, and Michael E. Daun. "Prophylaxis of Endophthalmitis/Response." Ophthalmic Surgery, Lasers and Imaging Retina 27, no. 1 (1996): 81–83. http://dx.doi.org/10.3928/1542-8877-19960101-16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Chung, Mina H. "ANTIBIOTIC PROPHYLAXIS: Author's response." Journal of the American Dental Association 140, no. 11 (2009): 1348–49. http://dx.doi.org/10.14219/jada.archive.2009.0062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Rothwell, Bruce R., and Darryl C. Tong. "ANTIBIOTIC PROPHYLAXIS: Authors' response." Journal of the American Dental Association 131, no. 6 (2000): 720. http://dx.doi.org/10.14219/jada.archive.2000.0259.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Nainar, S. M. Hashim, and Deborah A. Redford-Badwal. "Survey of Dental Prophylaxes Rendered by Pediatric Dentists in New England." Journal of Contemporary Dental Practice 5, no. 4 (2004): 14–22. http://dx.doi.org/10.5005/jcdp-5-4-14.

Full text

Abstract:

Abstract Background The objective of this anonymous postal survey was to assess the provision of dental prophylaxis by pediatric dentists in New England. Methods The questionnaire survey was sent by first class mail in September, 2001 to all 217 American Academy of Pediatric Dentistry (AAPD) members in active private practice in the six New England States of Connecticut, Massachusetts, Maine, New Hampshire, Rhode Island, and Vermont. A self-addressed, stamped envelope was provided to facilitate the returned response. Results The survey had a response rate of 70%. Most practitioners (93%) routi

APA, Harvard, Vancouver, ISO, and other styles

5

Eikelboom, John W., and Jack Hirsh. "Deep Vein Thrombosis Prophylaxis: Response." Chest 136, no. 6 (2009): 1700–1701. http://dx.doi.org/10.1378/chest.09-1970.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ghielmini, Michele, and Emanuele Zucca. "Response: CNS prophylaxis in MCL." Blood 114, no. 26 (2009): 5403–4. http://dx.doi.org/10.1182/blood-2009-10-245647.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Pushpakala, Jagannathan, Sasikala, Revathi, and Cherian Cyril. "ASSESS THE PREVALENCE AND PROPHYLAXIS RESPONSE TO NEEDLE STICK INJURY AMONG INTERNS IN A SELECTED TEACHING HOSPITAL, KELAMBAKKAM, KANCHIPURAM DISTRICT, TAMILNADU." International Journal of Current Research and Modern Education 2, no. 2 (2017): 62–64. https://doi.org/10.5281/zenodo.848251.

Full text

Abstract:

<strong>Aim: </strong>To assess the prevalence and prophylaxis response to needle stick injury among interns in a selected teaching hospital, Tamilnadu. Methods and Materials: A descriptive approach was used for the present study. The participants were about 104 medical and nursing interns and Convenience sampling technique was used. Data was collected by administering a structured questionnaire derived from WHO and modified according to the study. Results: Among the 104 samples 22(21%) of the interns had 1-3 injury in the past 12 months and 1(1%) of the interns had 4-5 injury in the past 12 m

APA, Harvard, Vancouver, ISO, and other styles

8

Sirven, Joseph I., Dean M. Wingerchuk, Joseph F. Drazkowski, Mark K. Lyons, and Richard S. Zimmerman. "Seizure Prophylaxis and Liability: In Response." Mayo Clinic Proceedings 80, no. 2 (2005): 291. http://dx.doi.org/10.4065/80.2.291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Gozdas, Hasan Tahsin. "Immune response following postexposure rabies prophylaxis." Human Vaccines & Immunotherapeutics 11, no. 7 (2015): 1878. http://dx.doi.org/10.1080/21645515.2015.1026525.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Liesegang, Thomas J. "Antibiotic Prophylaxis in Cataract Operations: In Response." Mayo Clinic Proceedings 72, no. 10 (1997): 997. http://dx.doi.org/10.4065/72.10.997.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Vallés, Jordi, and Ignacio Martin-Loeches. "Antibiotic Prophylaxis for Ventilator-Associated Pneumonia: Response." Chest 144, no. 5 (2013): 1735. http://dx.doi.org/10.1378/chest.13-1576.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Cober, Mary Petrea, and Stephanie J. Phelps. "Penicillin Prophylaxis in Children with Sickle Cell Disease." Journal of Pediatric Pharmacology and Therapeutics 15, no. 3 (2010): 152–59. http://dx.doi.org/10.5863/1551-6776-15.3.152.

Full text

Abstract:

Abstract Children who have sickle cell disease and are under the age of five years are at increased risk of life-threatening pneumococcal infection due to absent or non-functional spleens and a decreased immune response. To prevent pneumococcal infection, the American Academy of Pediatrics recommends the use of penicillin prophylaxis in children with sickle cell disease under the age of five and in older children who have had a previous severe pneumococcal infection or have functional/surgical asplenia. These recommendations are based on two landmark studies, the first evaluating the effective

APA, Harvard, Vancouver, ISO, and other styles

13

Utpat, Sandeepa, Fahad Hussain, Cem Dikengil, Nishka Utpat, and Vinod Nookala. "Antimalarial prophylaxis failure: Malaria in a returning traveler despite mefloquine prophylaxis." Tropical Parasitology 14, no. 1 (2024): 45–47. http://dx.doi.org/10.4103/tp.tp_39_23.

Full text

Abstract:

This case report presents a perplexing case of Plasmodium malariae breakthrough infection despite prophylaxis with appropriate antimalarial prophylactic regimen of mefloquine in a compliant patient. A 78-year-old missionary who travels each year to the African subcontinent for multiple weeks to months, over 25 years, adheres to stringent antimalarial prophylaxis with Mefloquine as prescribed, starting prior to the trip and continuing after the return to the U.S.A. She gave no prior history of malaria during her 25 years of travel to Africa and back. Since she had no prior history of malaria an

APA, Harvard, Vancouver, ISO, and other styles

14

Milosavljević, Zoran. "Viruses and social mistrust in the 21st century: What can HIV prevention teach us about the mistrust to COVID-19 vaccines?" Glasnik javnog zdravlja 98, no. 1 (2024): 88–100. http://dx.doi.org/10.5937/serbjph2401088m.

Full text

Abstract:

This article problematises similarities in social responses to two different types of prevention - antiretrovirals in the form of pre-exposure prophylaxis (PrEP) against HIV transmission, and the emerging COVID-19 vaccines against the SARS-COV2 virus. For the purpose of this article, I have revisited the work of Mary Douglas, British social anthropologist (1921-2007) on risk and social responses to risk. In the late 1980s, Mary Douglas described patterns and modalities of social response to risk in emerging epidemics. The same pattern of social dynamics and response could be followed in relati

APA, Harvard, Vancouver, ISO, and other styles

15

Brandeau, PhD, Margaret L., Gregory S. Zaric, PhD, Johannes Freiesleben, PhD, Frances L. Edwards, PhD, and Dena M. Bravata, MD, MS. "An ounce of prevention is worth a pound of cure: Improving communication to reduce mortality during bioterrorism responses." American Journal of Disaster Medicine 3, no. 2 (2008): 65–78. http://dx.doi.org/10.5055/ajdm.2008.0010.

Full text

Abstract:

Objective: To identify communication needs and evaluate the effectiveness of alternative communication strategies for bioterrorism responses.Methods: We provide a framework for evaluating communication needs during a bioterrorism response. Then, using a simulation model of a hypothetical response to anthrax bioterrorism in a large metropolitan area, we evaluate the costs and benefits of alternative strategies for communication during a response.Results: Expected mortality increases significantly with increases in the time for attack detection and announcement; decreases in the rate at which ex

APA, Harvard, Vancouver, ISO, and other styles

16

Roila, Fausto, Enzo Ballatori, Alessandra Fabi, et al. "Aprepitant (AP) versus dexamethasone (D) for preventing delayed emesis induced by anthracyclines plus cyclophosphamide (A+C) chemotherapy (CT) in breast cancer patients (pts): A double-blind, multicenter, randomized study." Journal of Clinical Oncology 31, no. 15_suppl (2013): 9614. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9614.

Full text

Abstract:

9614 Background: A combination of AP + a 5-HT3 receptor antagonist + D and AP alone is recommended, respectively, for the prophylaxis of acute and delayed emesis induced by A+C CT in breast cancer pts. In the registrative study the role of AP in delayed emesis was not defined because prophylaxis of acute emesis was different between the two arms, and the superiority of AP on delayed emesis could be the consequence of a dependent effect on the different results achieved in acute phase. Aim of this study was to compare the efficacy of AP versus D in preventing delayed emesis in pts receiving the

APA, Harvard, Vancouver, ISO, and other styles

17

Hegerl, U., G. Ulrich, and B. Müller-Oerlinghausen. "Auditory Evoked Potentials and Response to Lithium Prophylaxis." Pharmacopsychiatry 20, no. 05 (1987): 213–16. http://dx.doi.org/10.1055/s-2007-1017106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Podzamczer, Daniel. "In response: Prophylaxis of Pneumocystis Pneumonia and Toxoplasmosis." Annals of Internal Medicine 124, no. 12 (1996): 1096. http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Tulek, Necla, Halil Senocak, Arzu Yetkin, Hikmet Un, and Orhan Aylan. "Antibody response achieved by different rabies prophylaxis methods." International Journal of Infectious Diseases 10, no. 1 (2006): 87–88. http://dx.doi.org/10.1016/j.ijid.2005.02.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Priebe, Stefan, Christiane Wildgrube, and Bruno Müller-Oerlinghausen. "Lithium Prophylaxis and Expressed Emotion." British Journal of Psychiatry 154, no. 3 (1989): 396–99. http://dx.doi.org/10.1192/bjp.154.3.396.

Full text

Abstract:

Expressed emotion (EE) in key relatives of 21 patients with bipolar affective or schizoaffective psychoses was assessed by the CFI. All patients had been on prophylactic lithium for at least three years and were without psychotic symptoms at interview. The relationship between relatives' EE status and patients' course of illness was studied both retrospectively and prospectively. Two critical remarks designated high EE. The relatives' EE status was not related to number of hospital admissions or to severity and length of recurrences if the entire period of lithium treatment is considered as a

APA, Harvard, Vancouver, ISO, and other styles

21

Msema Bwire, George, and Kennedy Daniel Mwambete. "Immunological Perspectives of sub-Saharan Populations under Prophylaxis against Malaria." Immunology and Inflammation Diseases Therapy 3, no. 1 (2019): 01–03. http://dx.doi.org/10.31579/2637-8876/013.

Full text

Abstract:

Immunity is the state of protection against infectious disease conferred either through an immune response generated by immunization or previous infection. Generated immune responses may be long lasting even lifelong or gives immediate, but short-lived protection. In malaria-endemic areas, young children and pregnant women are particularly susceptible to malaria, but with exposures protective immunity against malaria develop although sterile immunity is never achieved. Assuring protection to vulnerable populations, prophylaxis against malaria is advocated to pregnancy women and sickle cell dis

APA, Harvard, Vancouver, ISO, and other styles

22

Paradiso-Hardy, Fran L., Patti Cornish, Chantal Pharand, and Stephen E. Fremes. "A National Survey of Antimicrobial Prophylaxis in Adult Cardiac Surgery Across Canada." Canadian Journal of Infectious Diseases 13, no. 1 (2002): 21–27. http://dx.doi.org/10.1155/2002/370389.

Full text

Abstract:

OBJECTIVE: To characterize national and regional patterns of antimicrobial prophylaxis in adult cardiac surgery across Canada.DESIGN: Retrospective, cross-sectional analysis.SETTING: Thirty-three adult cardiac surgical centres across Canada.INTERVENTIONS: A one-page questionnaire collecting information regarding institutional demographics and antimicrobial prophylaxis regimens for adult cardiac surgical procedures was mailed to all adult surgical centres across Canada. If a response was not received within one month, a second survey was mailed, followed by a telephone reminder within two weeks

APA, Harvard, Vancouver, ISO, and other styles

23

Margolis, Ellie, Hana Hakim, Jiangwei Yao, et al. "1771. Gut Resistome Changes in Response to Prophylactic Antibiotic Administration During Chemotherapy in Children With Acute Lymphoblastic Leukemia." Open Forum Infectious Diseases 5, suppl_1 (2018): S66. http://dx.doi.org/10.1093/ofid/ofy209.156.

Full text

Abstract:

Abstract Background Antibiotic resistance harbored in gut microbiome contributes to the emergence of multi–drug-resistant organisms (MDRO). Pediatric leukemia patients typically receive extensive antibiotics and are at higher risk for infection due to MDRO. Methods A prospective cohort of children (n = 242) with acute lymphoblastic leukemia self-collected stool samples at diagnosis and after induction chemothearpy. A third of patients (n = 69) underwent protocol-driven antibiotic prophylaxis: Levofloxacin (LV) given once neutropenia develops. With neutropenic fever patients on prophylaxis stop

APA, Harvard, Vancouver, ISO, and other styles

24

Ahmadzadeh, Afrouz, Line Kessel, Bo Simmendefeldt Schmidt, and Daniella Bach-Holm. "Steroid Response after Trabeculectomy—A Randomized Controlled Trial Comparing Dexamethasone to Diclofenac Eye Drops." Journal of Clinical Medicine 11, no. 24 (2022): 7365. http://dx.doi.org/10.3390/jcm11247365.

Full text

Abstract:

This prospective randomized controlled trial aimed to compare changes in intraocular pressure in three different anti-inflammatory regimens following trabeculectomy. Sixty-nine patients were randomized to receive either postoperative prophylaxis with topical preservative-free dexamethasone (DEX), diclofenac (DICLO), or their combination (DEX+DICLO). Our main outcome measure was an intraocular pressure (IOP) change of a minimum 4 mmHg following the withdrawal of anti-inflammatory prophylaxis 9 weeks after trabeculectomy. We found that the IOP decreased ≥ 4 mmHg in 18.6% of eyes after cessation

APA, Harvard, Vancouver, ISO, and other styles

25

Dagher, Hiba, Anne-Marie Chaftari, Andrea Haddad, et al. "Outcome Analysis of Breakthrough Invasive Aspergillosis on Anti-Mold Azole Prophylaxis and Treatment: 30-Year Experience in Hematologic Malignancy Patients." Journal of Fungi 11, no. 2 (2025): 160. https://doi.org/10.3390/jof11020160.

Full text

Abstract:

Background: Anti-mold azoles have improved the outcomes of invasive aspergillosis (IA) when used therapeutically, but they are extensively used as prophylaxis. There are limited data regarding the outcomes of patients with hematologic malignancy who develop breakthrough IA on anti-mold azoles. We aimed to determine whether breakthrough IA on azole prophylaxis shows worse outcomes compared to no prophylaxis. Methods: We compared outcomes including therapy response and mortality between antifungal regimens in hematologic malignancy patients with IA between July 1993 and July 2023. Results: Compa

APA, Harvard, Vancouver, ISO, and other styles

26

Roila, Fausto, Benedetta Ruggeri, Enzo Ballatori, Albano Del Favero, and Maurizio Tonato. "Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study." Journal of Clinical Oncology 32, no. 2 (2014): 101–6. http://dx.doi.org/10.1200/jco.2013.51.4547.

Full text

Abstract:

PurposeA combination of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone is recommended for the prophylaxis of acute or delayed emesis induced by chemotherapy containing anthracyclines plus cyclophosphamide in patients with breast cancer. The aim of this study was to verify whether dexamethasone is superior to aprepitant in preventing delayed emesis in patients receiving the same prophylaxis for acute emesis.Patients and MethodsA randomized double-blind study comparing aprepitant versus dexamethasone was completed in chemotherapy-naive patients with breast cancer treated with anthrac

APA, Harvard, Vancouver, ISO, and other styles

27

van der Kuy, P.-HM, and JJHM Lohman. "A Quantification of the Placebo Response in Migraine Prophylaxis." Cephalalgia 22, no. 4 (2002): 265–70. http://dx.doi.org/10.1046/j.1468-2982.2002.00363.x.

Full text

Abstract:

To quantify the placebo response of prophylactic therapy in migraine, a meta-analysis of prophylactic, double-blind, placebo controlled migraine studies was performed. The total analysis included 22 studies testing 19 different products, including 2013 patients, of which 828 were treated with placebo. A reduction in migraine attacks of 50% or more (responders) was seen in 23.5% ± 8.0 (95% C.I. 18.3-28.8%) of the patients in the placebo groups and 45.5% ± 15.5 (95% C.I. 37.4-53.6%) in the active groups. A reduction in migraine attacks of 16.8% ± 12.7 (95% C.I. 10.9-22.6%) was observed in the pl

APA, Harvard, Vancouver, ISO, and other styles

28

Rath, Charlotte Lützhøft, Niklas Rye Jørgensen, and Troels Wienecke. "Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response." Journal of Stroke and Cerebrovascular Diseases 27, no. 10 (2018): 2683–90. http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.05.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Leissinger, Cindy A., Alessandro Gringeri, Leonard A. Valentino, and Paolo A. Cortesi. "Joint Disease and the Potential for Improved Joint Health in Inhibitor Patients Who Have a Good Response to aPCC Prophylaxis: Data From the Profeiba Study." Blood 120, no. 21 (2012): 3374. http://dx.doi.org/10.1182/blood.v120.21.3374.3374.

Full text

Abstract:

Abstract Abstract 3374 Patients with hemophilia A and factor VIII inhibitors are at increased risk for repetitive, poorly controlled joint bleeding and progression to end-stage joint disease. The investigator-initiated, prospective, randomized, crossover Prophylaxis with Factor Eight Inhibitor Bypassing Activity (Pro-FEIBA) study showed that prophylaxis with activated prothrombin complex concentrates (aPCC) infused at a target dose of 85 U/kg (±15%) on 3 nonconsecutive days per week safely reduced the frequency of hemarthroses and target joint bleeding by 61% and 72%, respectively (P<0.001)

APA, Harvard, Vancouver, ISO, and other styles

30

Maiese, Aniello, Giovanna Passaro, Alessandra DE Matteis, Valentina Fazio, La Russa Raffaele, and Marco Di Paolo. "Thromboinflammatory response in SARS-CoV-2 sepsis." Medico-Legal Journal 88, no. 2 (2020): 78–80. http://dx.doi.org/10.1177/0025817220926915.

Full text

Abstract:

Viral sepsis is rare, and its real incidence is not known. SARS-CoV-2 infection causes the release of a significant amount of pro-inflammatory cytokines that aggravates interstitial pneumonia and evolves in viral sepsis with prominent hypercoagulability. We believe it is useful and advisable to establish early immunomodulator therapy and the prophylaxis anticoagulant therapy should be rethought.

APA, Harvard, Vancouver, ISO, and other styles

31

Hassouna, HabiBA, Kyle Brizendine, and Vasilios Athans. "Real-World Use – Isavuconazole at a Large Academic Medical Center." Open Forum Infectious Diseases 4, suppl_1 (2017): S82. http://dx.doi.org/10.1093/ofid/ofx163.028.

Full text

Abstract:

Abstract Background Invasive fungal infections cause significant mortality and morbidity. Isavuconazole (ISV) is a new triazole approved for treatment of mucormycosis and aspergillosis. Data on its effectiveness outside clinical trials and in patients receiving prior triazole prophylaxis are lacking. Methods We conducted a retrospective cohort study on all patients at the Cleveland Clinic 6/1/2015–1/31/2017 who received ISV to determine 6-week response in a population with varying underlying diseases, and previous triazole prophylaxis or treatment. Descriptive statistics and univariate associa

APA, Harvard, Vancouver, ISO, and other styles

32

Singanal, Sharanabasappa, Anand R. Kanaki, and Bindushree A. R. "Knowledge and practice of antibiotic prophylaxis for infective endocarditis among dental students." International Journal of Basic & Clinical Pharmacology 6, no. 9 (2017): 2167. http://dx.doi.org/10.18203/2319-2003.ijbcp20173738.

Full text

Abstract:

Background: Infective endocarditis (IE) is a microbial infection of the valves and endocardium of the heart. IE is difficult to treat and has a poor prognosis. Dentists play a major role in preventing IE in susceptible patients. In this study, we evaluate knowledge and practice of antibiotic prophylaxis for IE among dental students, interns and PGs at S. N. Dental College, Kalaburagi.Methods: A cross-sectional study was done by survey using questionnaire. Questionnaire was distributed to 159 dental students, interns and PGs at S. N. Dental College, Kalaburagi. Questionnaire included questions

APA, Harvard, Vancouver, ISO, and other styles

33

Lucetti, C., A. Nuti, N. Pavese, G. Gambaccini, G. Rossi, and U. Bonuccelli. "Flunarizine in Migraine Prophylaxis: Predictive Factors for A Positive Response." Cephalalgia 18, no. 6 (1998): 349–52. http://dx.doi.org/10.1046/j.1468-2982.1998.1806349.x.

Full text

Abstract:

The efficacy of flunarizine in migraine prophylaxis is confirmed in both open and controlled trials. However, it is unknown what factors may influence a good response to prophylaxis with flunarizine. The aim of this study was to determine the possible predictive factors for therapeutic responsiveness to 3 months' treatment with flunarizine. One-hundred headache patients treated with flunarizine were evaluated. We considered “responders” those patients who recorded a reduction in migraine frequency of 75% after treatment. Statistical analysis revealed four factors which might influence therapeu

APA, Harvard, Vancouver, ISO, and other styles

34

Baethge, Christopher, Leonardo Tondo, Irene M. Bratti, et al. "Prophylaxis Latency and Outcome in Bipolar Disorders." Canadian Journal of Psychiatry 48, no. 7 (2003): 449–57. http://dx.doi.org/10.1177/070674370304800704.

Full text

Abstract:

Objective: To analyze new and reviewed findings to evaluate relations between treatment response and latency from onset of bipolar disorder (BD) to the start of mood-stabilizer prophylaxis. Method: We analyzed our own new data and added findings from research reports identified by computerized searching. Results: We found 11 relevant studies, involving 1485 adult patients diagnosed primarily with BD. Reported latency to prophylaxis averaged 9.6 years (SD 1.3), and follow-up in treatment averaged 5.4 years (SD 3.1). Greater illness intensity and shorter treatment latency were closely associated

APA, Harvard, Vancouver, ISO, and other styles

35

Lipton, Richard B., Patricia Pozo-Rosich, Andrew M. Blumenfeld, et al. "Rates of Response to Atogepant for Migraine Prophylaxis Among Adults." JAMA Network Open 5, no. 6 (2022): e2215499. http://dx.doi.org/10.1001/jamanetworkopen.2022.15499.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Lipsky, Lior, and Graham Barrett. "Intracameral antibiotics for prophylaxis of postoperative endophthalmitis in Australia: Response." Clinical & Experimental Ophthalmology 48, no. 1 (2019): 139–40. http://dx.doi.org/10.1111/ceo.13656.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Grant-Kels, Jane M. "Response to: “Risks of hydroxychloroquine use for COVID-19 prophylaxis”." Journal of the American Academy of Dermatology 83, no. 1 (2020): e75-e76. http://dx.doi.org/10.1016/j.jaad.2020.04.112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Macedo, Ana, Josep-E. Baños, and Magí Farré. "Placebo response in the prophylaxis of migraine: A meta-analysis." European Journal of Pain 12, no. 1 (2008): 68–75. http://dx.doi.org/10.1016/j.ejpain.2007.03.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Limper, Andrew H. "Routine Pneumocystis Pneumonia Prophylaxis in Patients Treated With Rituximab?: Response." Chest 144, no. 1 (2013): 360. http://dx.doi.org/10.1378/chest.13-0776.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Farbod, F. "A response to “Amoxicillin prophylaxis is not associated with anaphylaxis”." International Journal of Oral and Maxillofacial Surgery 39, no. 5 (2010): 520–21. http://dx.doi.org/10.1016/j.ijom.2010.01.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Serretti, Alessandro, Enrico Lattuada, Linda Franchini, and Enrico Smeraldi. "Melancholic features and response to lithium prophylaxis in mood disorders." Depression and Anxiety 11, no. 2 (2000): 73–79. http://dx.doi.org/10.1002/(sici)1520-6394(2000)11:2<73::aid-da4>3.0.co;2-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Rybakowski, Janusz K., Aleksandra Suwalska, Maria Skibinska, Monika Dmitrzak-Weglarz, Anna Leszczynska-Rodziewicz, and Joanna Hauser. "Response to lithium prophylaxis: Interaction between serotonin transporter andBDNF genes." American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 144B, no. 6 (2007): 820–23. http://dx.doi.org/10.1002/ajmg.b.30420.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Kumar, Shaji K., Angela Dispenzieri, Martha Q. Lacy, et al. "Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation." Blood 120, no. 21 (2012): 3138. http://dx.doi.org/10.1182/blood.v120.21.3138.3138.

Full text

Abstract:

Abstract Abstract 3138 Background: Several recent reports have suggested that doxycycline can inhibit amyloid fibril formation in different in vitro and in vivo model systems. Doxycycline is the antibiotic of choice for infectious disease prophylaxis in patients with penicillin allergy, following autologous peripheral blood stem cell transplantation for various hematological malignancies. We examined the outcome of patients with light chain amyloidosis (AL) undergoing autologous stem cell transplantation to study the impact of doxycycline used as antibacterial prophylaxis. Patients and methods

APA, Harvard, Vancouver, ISO, and other styles

44

Strbo, Natasa, Laura Romero, Eckhard R. Podack, Eileen F. Villasante, Kimberly A. Edgel, and Natasa Strbo. "Secreted heat shock protein gp96-Ig vaccine for malaria prophylaxis." Journal of Immunology 196, no. 1_Supplement (2016): 146.10. http://dx.doi.org/10.4049/jimmunol.196.supp.146.10.

Full text

Abstract:

Abstract Proposed vaccine principle relies on secreted gp96-Ig chaperoning Plasmodium falciparum (Pf) AMA1 and PfCSP sporozoite proteins that are efficiently taken up and cross presented by activated DC via MHC I to CD8 CTL, thereby stimulating an avid, antigen specific, cytotoxic T cell response. The generation of a powerful, cytotoxic anti-sporozoite CD8 CTL response by the vaccine is expected to provide prophylactic immunity against malaria by killing infected liver cells, thereby preventing blood stage infection. We performed mouse immunogenicity experiments using 293-gp96-IgPfAMA1-PfCSP v

APA, Harvard, Vancouver, ISO, and other styles

45

Mongelli, Michele, Domenica Lorusso, Vanna Zanagnolo, Sandro Pignata, Nicoletta Colombo, and Gennaro Cormio. "Venous Thromboembolism Prophylaxis in Gynecologic Oncology: A MITO-MaNGO Survey." Diagnostics 14, no. 11 (2024): 1159. http://dx.doi.org/10.3390/diagnostics14111159.

Full text

Abstract:

Cancer-associated thrombosis is the second leading cause of death in cancer patients, and its incidence has been increasing in recent years. This survey was aimed at gathering information regarding the management of thromboembolic prophylaxis within the MITO (Multicenter Italian Trials in Ovarian Cancer)-MaNGO (Mario Negri Gynecologic Oncology) groups. We designed a self-administered, multiple-choice online questionnaire available only for MITO-MaNGO members for one month, starting in May 2022 and ending in June 2022. We processed one response form per center, and 50 responses were analyzed, w

APA, Harvard, Vancouver, ISO, and other styles

46

Cuttler, Jerry M., and Ludwig E. Feinendegen. "Commentary on Inhaled ²³⁹PuO₂ in Dogs — A Prophylaxis against Lung Cancer?" Dose-Response 1, no. -1 (2015): 1–8. http://dx.doi.org/10.2203/dose-response.15-003.cuttler.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Liu, Xinnong, Soriba Naby Camara, Mamady Diakite, Denis Bernard Raiche, and Zhujiazi Zhang. "Knowledge, attitude, and practice regarding venous thromboembolism prophylaxis: A multicenter cross-sectional study of medical staff in Guinea." PLOS One 20, no. 4 (2025): e0319855. https://doi.org/10.1371/journal.pone.0319855.

Full text

Abstract:

Objectives To investigate the awareness of medical staff regarding venous thromboembolism (VTE) prophylaxis in Guinea. Methods The survey was completed from June 1, 2023 to August 1, 2023 through filling out self-designed questionnaire including four parts containing demographic data, knowledge, attitude, and practice regarding VTE prophylaxis. Cronbach’s alpha values were used to analyze the internal consistency of the questionnaire. The results were analyzed using chi-square tests at a 95% significance level. Results Of the 245 medical staff invited to participate in the survey, 211 (86.1%)

APA, Harvard, Vancouver, ISO, and other styles

48

Skorupan, Nebojša, Surabhi Ranjan, Seema Mehta, et al. "Pneumocystis jirovecii prophylaxis in patients treated for high-grade gliomas: a survey among neuro-oncologists." Neuro-Oncology Practice 6, no. 4 (2018): 321–26. http://dx.doi.org/10.1093/nop/npy049.

Full text

Abstract:

Abstract Background Pneumocystis jirovecii pneumonia (PJP) is a known complication in patients with high-grade gliomas (HGGs) who are treated with radiation and chemotherapy. PJP prophylaxis is commonly recommended, but there are currently no clear guidelines regarding duration of treatment and choice of drugs. This study aimed to assess current practice patterns of PJP prophylaxis among neuro-oncologists. Methods An online survey of 14 multiple choice questions was sent to 207 neuro-oncologists and medical oncologists treating brain cancers at all National Cancer Institute-designated cancer c

APA, Harvard, Vancouver, ISO, and other styles

49

Brandwein, Joseph, Elena Liew, David Page, and Peng Wang. "Infectious Complications and Antibiotic Prophylaxis during Induction Therapy with Venetoclax Plus Azacitidine for Previously Untreated AML: A Real-World Experience." Blood 144, Supplement 1 (2024): 5971. https://doi.org/10.1182/blood-2024-199315.

Full text

Abstract:

Venetoclax + azacitidine (ven-aza) induction therapy has become the standard of care at many centers for AML patients who are unfit for intensive induction therapy. Although widely utilized, the efficacy of antimicrobial prophylaxis during induction with this regimen has not been clearly determined. We retrospectively evaluated infectious complications during ven-aza induction therapy in all previously untreated AML patients receiving this regimen at the University of Alberta Hospital, Alberta, Canada from August 2020 - June 2024. There were 93 patients; the median age was 76 (range 58-90) yea

APA, Harvard, Vancouver, ISO, and other styles

50

Kessing, Lars Vedel, Eleni Vradi, and Per Kragh Andersen. "Starting lithium prophylaxis earlyv.late in bipolar disorder." British Journal of Psychiatry 205, no. 3 (2014): 214–20. http://dx.doi.org/10.1192/bjp.bp.113.142802.

Full text

Abstract:

BackgroundNo study has investigated when preventive treatment with lithium should be initiated in bipolar disorder.AimsTo compare response rates among patients with bipolar disorder starting treatment with lithium earlyv.late.MethodNationwide registers were used to identify all patients with a diagnosis of bipolar disorder in psychiatric hospital settings who were prescribed lithium during the period 1995–2012 in Denmark (n= 4714). Lithium responders were defined as patients who, following a stabilisation lithium start-up period of 6 months, continued lithium monotherapy without being admitted

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!